<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01066468</url>
  </required_header>
  <id_info>
    <org_study_id>CSTI571A2110</org_study_id>
    <secondary_id>2010-018418-53</secondary_id>
    <nct_id>NCT01066468</nct_id>
  </id_info>
  <brief_title>Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec® Indicated Hematological Disorders.</brief_title>
  <official_title>A Non-randomized, Open-label Study to Characterize the Pharmacokinetics (PK) of Glivec/Gleevec® (Imatinib Mesylate) in Pediatric (Age Range 1 to Less Than 4 Years) Patients With Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) or Other Glivec/ Gleevec® Indicated Hematological Disorders (HES, CEL, MDS/ MPN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the pharmacokinetics of imatinib in pediatric patients ages 1 to &lt;4
      years of age to help develop dosing regimens
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>October 2010</start_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure: Pharmacokinetic data o (CL/F (clearance) o V/F (Volume of distribution) o Tmax o Physiologically based pharmacokinetic (PBPK) parameters (plasma protein binding and α-1 acid glycoprotein concentration)</measure>
    <time_frame>2 PK sample collection within 21 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>safety and tolerability of imatinib during the study period</measure>
    <time_frame>study period of 21 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Chronic Myeloid Leukemia (CML)</condition>
  <condition>Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)</condition>
  <condition>Other Glivec/Gleevec Indicated Hematological Disorders (HES, CEL, MDS/ MPN)</condition>
  <arm_group>
    <arm_group_label>Gleevec/Glivec</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gleevec/Glivec</intervention_name>
    <arm_group_label>Gleevec/Glivec</arm_group_label>
    <other_name>STI571</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients must be 1 to less than 4 years of age at study entry

          2. Written informed consent must be signed by the patient's parent or legal guardian.

          3. Patients must have the diagnosis of CML or Ph+ ALL

          4. Lansky score must be ≥ 50 (Table7-2)

          5. Patient must have adequate end organ function as defined by

               -  Total bilirubin &lt; 1.5 x ULN

               -  SGPT (ALT) and SGOT (AST) &lt; 2.5 x UNL

               -  Creatinine &lt; 1.5 x ULN

        Exclusion Criteria:

          1. Patients who have received drugs a) known to be metabolized by CYP3A4 or 3A5, b) are
             CYP inhibitors and inducers, within 2 weeks prior to Visit 2 (except for imatinib)

          2. Patients who previously received radiotherapy to ≥ 25% of the bone marrow, with the
             exception of patients who received total body radiation as part of a preparatory
             regimen for hematopoetic stem cell transplant (HSCT)

          3. Patients receiving antibacterial and antipyretic medication to treat active infection

          4. Patients with International normalized ratio (INR) or partial thromboplastin time
             (PTT) &gt; 1.5 x ULN, with the exception of patients on treatment with oral
             anticoagulants

          5. Patients whose parents or legal guardians, in the opinion of the Investigator, were
             unlikely to comply with the protocol or safety monitoring requirements

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>3 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>117997</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Netherlands</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2010</study_first_submitted>
  <study_first_submitted_qc>February 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2010</study_first_posted>
  <last_update_submitted>March 12, 2012</last_update_submitted>
  <last_update_submitted_qc>March 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic myeloid leukemia</keyword>
  <keyword>CML</keyword>
  <keyword>Philadelphia chromosome positive</keyword>
  <keyword>acute lymphoblastic leukemia</keyword>
  <keyword>PhGlivec,</keyword>
  <keyword>Gleevec,</keyword>
  <keyword>hypereosinophilic syndrome,</keyword>
  <keyword>HES,</keyword>
  <keyword>chronic eosinophilic leukemia,</keyword>
  <keyword>CEL,</keyword>
  <keyword>myelodysplastic syndrome,</keyword>
  <keyword>MDS,</keyword>
  <keyword>myeloproliferative disease,</keyword>
  <keyword>MPD+ ALL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Philadelphia Chromosome</mesh_term>
    <mesh_term>Hematologic Diseases</mesh_term>
    <mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

